Showing results (241-250 of 601) with videos related to

Sort By:
Pageof 61
Metal-Based Drugs|January 1, 1994
In vitro antitumour activity of some triorganophosphinegold(i) thionucleobasesE R Tiekink, P D Cookson, B M Linahan, et al.
Journal of Plastic, Reconstructive & Aesthetic Surgery : JPRAS|September 25, 2024
COVID-19 and postoperative complications after plastic surgery procedures: More than just hypercoagulabilityTheresa K Webster, Lauren S Lowe, Dylan K Kim, et al.
British Journal of Haematology|September 1, 1992
Effect of orally active hydroxypyridinone iron chelators on human lymphocyte functionK Pattanapanyasat, H K Webster, P Tongtawe, et al.
Lancet (London, England)|November 19, 1988
Graves' disease of the beta cell: glucose dysregulation due to islet-cell stimulating antibodiesT J Wilkin, P Hammonds, I Mirza, et al.
American Journal of Obstetrics and Gynecology|April 16, 1998
Fetal oxygen saturation and fractional extraction at birth and the relationship to measures of acidosisB Richardson, A Nodwell, K Webster, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1997
Low-dose intravenous ondansetron (8 mg) plus dexamethasone: an effective regimen for the control of carboplatin-induced emesisM Markman, A Kennedy, K Webster, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2000
Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer CenterM Markman, A Kennedy, K Webster, et al.
Anti-Cancer Drug Design|May 17, 2001
Synthesis, DNA binding and cytotoxicity of isohelical DNA groove binding platinum complexesN J Wheate, L K Webster, C R Brodie, et al.
Journal of Cancer Research and Clinical Oncology|February 24, 2001
Neurotoxicity associated with a regimen of carboplatin (AUC 5-6) and paclitaxel (175 mg/m2 over 3 h) employed in the treatment of gynecologic malignanciesM Markman, A Kennedy, K Webster, et al.
Pageof 61